Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Prime Medicine (Nasdaq: PRME) announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL.
A live audio webcast and 90-day replay will be available in the News & Events section of Prime Medicine’s website.
Positive
- None.
Negative
- None.
News Market Reaction – PRME
In the Jun 3 session, PRME declined 2.18%, reflecting a moderate negative market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 55 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Investor conference | Positive | +3.0% | CEO fireside chat at Jefferies Global Healthcare Conference with webcast access. |
| May 07 | Earnings & updates | Negative | -8.7% | Q1 2026 financial results with sizeable net loss and program timing guidance. |
| Apr 16 | CFO appointment | Positive | -3.2% | Appointment of experienced CFO to support upcoming clinical and strategic plans. |
| Mar 03 | Full-year earnings | Negative | -9.2% | Full-year 2025 results highlighting large net loss and funding needs. |
| Feb 25 | Investor conferences | Positive | +7.8% | Announcement of multiple early-March investor conference appearances with webcasts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows shares often declining on earnings and some corporate updates, but reacting positively to investor conference participation.
Over the last several months, Prime Medicine has mixed market reactions to news. Investor conference announcements on Feb 25 and May 28 coincided with gains of 7.83% and 3.03%, while earnings updates on Mar 3 and May 7 saw declines of 9.23% and 8.65%. The CFO appointment on Apr 16 was strategically positive but met a modest selloff. Today’s conference appearance fits the pattern of active investor outreach, though the pre-news price move diverges from prior positive reactions to similar conference announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL.
A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the event.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
